当前位置： SCI文献检索 > INFLAMMATORY BOWEL DISEASES期刊下所有文献 > Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients.

Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients.

Abstract：

BACKGROUND:This study examines the resources utilization in patients with Crohn's disease (CD) during the year before (Y - 1) and after (Y + 1) starting treatment with adalimumab and the drug's efficiency. METHODS:Observational, multicenter, prospective cohort study of patients with CD naive to biological drugs. The proportion of patients with CD Activity Index (CDAI) <150 was considered as the effectiveness variable. Costs considered were direct costs (DC) related to the use of health care resources, and indirect costs (IC) related to sick leave in Y - 1 and Y + 1. Adalimumab efficiency was estimated as the incremental cost/effectiveness ratio. A deterministic sensitivity analysis was performed building 3 scenarios: base case, the least favorable, and the most favorable case for adalimumab. RESULTS:In the cohort of 126 patients (50.8% men; age 39.1 ± 13.8 yr), the proportion of patients in remission increased from 34.1% by the end of Y - 1 to 83.3% by the end of Y + 1. Although the DC increase by the use of adalimumab, the use of doctor visits, emergency room visits, laboratory tests, diagnostic examinations, and nonbiological drug treatment were lower (P < 0.05) in Y + 1 than Y - 1. In the base case scenario, considering only DC, the incremental cost/effectiveness ratio was €31,308 and including IC, it was €28,936. In patients with CDAI > 150 at the onset, incremental cost/effectiveness ratio was €20,119 and €18,223, considering DC alone or included IC, respectively. CONCLUSIONS:In patients with CD, adalimumab increases pharmacological costs at the expense of biological therapy but reduces the cost of other drugs, the use of health care resources, and IC. Adalimumab efficiency is 30% greater in patients with CDAI > 150.

journal_name

Inflamm Bowel Dis

journal_title

Inflammatory bowel diseases

authors

Saro C,Ceballos D,Muñoz F,De la Coba C,Aguilar MD,Lázaro P,Iglesias-Flores E,Barreiro-de Acosta M,Hernández-Durán MD,Barrio J,Riestra S,Fernández Salazar L,EFICADEC Researchers Group.

doi

10.1097/MIB.0000000000000413

subject

Has Abstract

pub_date

2015-07-01 00:00:00

pages

1631-40

issue

eissn

1078-0998

issn

1536-4844

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients.